Home

Bio-Techne Corp - Common Stock (TECH)

50.39
+0.52 (1.03%)
NASDAQ · Last Trade: Aug 7th, 9:45 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close49.87
Open50.51
Bid50.00
Ask50.76
Day's Range50.39 - 50.51
52 Week Range46.01 - 80.95
Volume37,346
Market Cap8.01B
PE Ratio (TTM)60.70
EPS (TTM)0.8
Dividend & Yield0.3200 (0.64%)
1 Month Average Volume2,298,711

Chart

About Bio-Techne Corp - Common Stock (TECH)

Bio-Techne Corp is a biotechnology company that specializes in developing and producing high-quality biotechnology tools and reagents for the life sciences market. The company offers a wide range of products, including proteins, antibodies, assays, and diagnostic tools, which are used by researchers and clinical laboratories for various applications, such as drug development, diagnostics, and disease research. With a focus on innovation, Bio-Techne aims to provide cutting-edge solutions that enhance research capabilities and improve patient outcomes in healthcare. Read More

News & Press Releases

1 Healthcare Stock on Our Watchlist and 2 We Find Risky
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 13.8%. This drop is a far cry from the S&P 500’s 5.3% ascent.
Via StockStory · August 7, 2025
Bio-Techne (TECH) Q4 EPS Rises 8.2%fool.com
Via The Motley Fool · August 6, 2025
Why Bio-Techne (TECH) Shares Are Plunging Today
Shares of life sciences company Bio-Techne (NASDAQ:TECH) fell 6.5% in the afternoon session after the company reported its fourth-quarter fiscal 2025 results, which included a significant net loss driven by a large impairment charge. The company posted a net loss of $17.68 million, a sharp reversal from the $40.59 million in net income recorded a year ago. This loss resulted from an $83.1 million impairment charge linked to the divestiture of its Exosome Diagnostics business. An impairment charge is an accounting entry used when an asset's value falls below its recorded worth. Furthermore, the company's gross margin tightened and it recorded an operating loss of $23.9 million, compared to an operating profit of $45.8 million in the prior year. The Diagnostics and Spatial Biology division also experienced a 1% decrease in sales.
Via StockStory · August 6, 2025
Earnings Scheduled For August 6, 2025benzinga.com
Via Benzinga · August 6, 2025
Which S&P500 stocks are moving on Wednesday?chartmill.com
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · August 6, 2025
What's going on in today's session: S&P500 gap up and gap down stockschartmill.com
Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · August 6, 2025
Bio-Techne (NASDAQ:TECH) Exceeds Q2 Expectations
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 3.5% year on year to $317 million. Its non-GAAP profit of $0.53 per share was 6.1% above analysts’ consensus estimates.
Via StockStory · August 6, 2025
These S&P500 stocks that are showing activity before the opening bell on Wednesday.chartmill.com
Pre-market stock analysis of S&P500 stocks on 2025-08-06: top gainers and losers in today's session.
Via Chartmill · August 6, 2025
Bio-Techne Corp (NASDAQ:TECH) Reports Mixed Q4 2025 Earnings Amid Revenue Miss and EPS Beatchartmill.com
Bio-Techne Corp (TECH) reported mixed Q4 2025 earnings, missing revenue estimates but beating EPS. Stock fell 2.1% pre-market amid growth concerns.
Via Chartmill · August 6, 2025
Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow
Life sciences company Bio-Techne (NASDAQ:TECH) will be reporting results this Wednesday before market open. Here’s what investors should know.
Via StockStory · August 4, 2025
1 Mooning Stock with Exciting Potential and 2 That Underwhelm
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media following.
Via StockStory · July 28, 2025
Fortrea, Azenta, Bio-Techne, 10x Genomics, and Amphastar Pharmaceuticals Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after a new trade agreement between the United States and Japan spurred a broad market rally. 
Via StockStory · July 23, 2025
Bio-Techne (TECH) Stock Is Up, What You Need To Know
Shares of life sciences company Bio-Techne (NASDAQ:TECH) jumped 4.6% in the afternoon session after the investment firm Stephens initiated coverage on the stock with an "overweight" rating and a $65.00 price target. 
Via StockStory · July 22, 2025
What's going on in today's session: S&P500 moverschartmill.com
Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.
Via Chartmill · July 21, 2025
Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology
Spear Bio, a biotechnology company pioneering homogeneous ultrasensitive immunoassay technology, is pleased to announce a strategic distribution partnership with Bio-Techne Corporation (NASDAQ: TECH), a global leading provider of innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. The partnership significantly expands global access to Spear Bio’s groundbreaking SPEAR UltraDetect™ immunoassays, focusing initially on the neurology research market. The introductory SPEAR UltraDetect offering targets biomarkers pivotal to neurodegenerative diseases, such as phosphorylated tau 231 (pTau 231), phosphorylated tau 217 (pTau 217), glial fibrillary acidic protein (GFAP), and neurofilament light (Nf‑L). This partnership follows Bio-Techne's participation in Spear Bio’s $45 million Series A funding round in 2024.
By Spear Bio · Via Business Wire · July 15, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.
Via Chartmill · July 10, 2025
What's going on in today's session: S&P500 moverschartmill.com
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.
Via Chartmill · July 10, 2025
Assessing Bio-Techne: Insights From 7 Financial Analystsbenzinga.com
Via Benzinga · July 9, 2025
BIO-TECHNE CORP (NASDAQ:TECH) – A Quality Stock with Strong Fundamentalschartmill.com
BIO-TECHNE CORP (NASDAQ:TECH) is a quality stock with strong revenue growth, high ROIC, and solid profitability, making it a candidate for long-term investors.
Via Chartmill · July 9, 2025
Top S&P500 movers in Monday's sessionchartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Monday.
Via Chartmill · July 7, 2025
1 S&P 500 Stock to Research Further and 2 to Keep Off Your Radar
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · July 3, 2025
Top S&P500 movers in Friday's sessionchartmill.com
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.
Via Chartmill · June 27, 2025
Gapping S&P500 stocks in Friday's sessionchartmill.com
Curious about the market action on Friday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Via Chartmill · June 27, 2025
TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts
Life sciences company Bio-Techne (NASDAQ:TECH) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 4.2% year on year to $316.2 million. Its non-GAAP profit of $0.56 per share was 10.4% above analysts’ consensus estimates.
Via StockStory · June 10, 2025
Thursday's session: top gainers and losers in the S&P500 indexchartmill.com
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · June 5, 2025